Nobody ever questions-Polypharmacy in care homes: A mixed methods evaluation of a multidisciplinary medicines optimisation initiative

Sue Jordan, Hayley Prout, Neil Carter, John Dicomidis, Jamie Hayes, Jeffrey Round, Andrew Carson-Stevens, Sue Jordan, Hayley Prout, Neil Carter, John Dicomidis, Jamie Hayes, Jeffrey Round, Andrew Carson-Stevens

Abstract

Background: Nurse-led monitoring of patients for signs and symptoms associated with documented 'undesirable effects' of medicines has potential to prevent avoidable harm, and optimise prescribing.

Intervention: The Adverse Drug Reaction Profile for polypharmacy (ADRe-p) identifies and documents putative adverse effects of medicines commonly prescribed in primary care. Nurses address some problems, before passing ADRe-p to pharmacists and prescribers for review, in conjunction with prescriptions.

Objectives: We investigated changes in: the number and nature of residents' problems as recorded on ADRe-p; prescription regimens; medicines optimisation: and healthcare costs. We explored aetiologies of problems identified and stakeholders' perspectives.

Setting and participants: In three UK care homes, 19 residents completed the study, December 2018 to May 2019. Two service users, three pharmacists, six nurses gave interviews.

Methods: This mixed-method process evaluation integrated data from residents' ADRe-ps and medicines charts, at the study's start and 5-10 weeks later.

Results: We recruited three of 27 homes approached and 26 of 45 eligible residents; 19 completed ADRe-p at least twice. Clinical gains were identified for 17/19 residents (mean number of symptoms 3 SD 1.67, range 0-7). Examples included management of: pain (six residents), seizures (three), dyspnoea (one), diarrhoea (laxatives reduced, two), falls (two of five able to stand). One or more medicine was de-prescribed or dose reduced for 12/19 residents. ADRe administration and review cost ~£30 in staff time. ADRe-p helped carers and nurses bring residents' problems to the attention of prescribers.

Implications: ADRe-p relieved unnecessary suffering. It supported carers and nurses by providing a tool to engage with pharmacists and prescribers, and was the only observable strategy for multidisciplinary team working around medicines optimisation. ADRe-p improved care by: a) regular systematic checks and problem documentation; b) information transfer from care home staff to prescribers and pharmacists; c) recording changes.

Registration: NLM Identifier NCT03955133; ClinicalTrials.gov.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. How ADRe works.
Fig 1. How ADRe works.
Fig 2
Fig 2
a. Care home recruitment: Flow diagram. b. Resident recruitment: Flow diagram.
Fig 3
Fig 3
a. Linking problem to solutions, example 1: ADRe’s information used—no more falls. b. ADRe’s information not used—nosebleeds continue. Medicines underlined were discontinued or reduced. Medicines italicised were started or increased. Aetiologies emboldened were the most pertinent to the resident.

References

    1. WHO: Medication Without Harm—Global Patient Safety Challenge on Medication Safety. Geneva: World Health Organization, 2017. Licence: CC BY-NC-SA 3.0 IGO.
    1. Jordan S, Banner T, Gabe-Walters M, Mikhail JM, Round J, Snelgrove S, et al. Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines. BMJ open. 2018; 8(9):e023377 10.1136/bmjopen-2018-023377
    1. Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D: Adverse drug reactions, power, harm reduction, regulation and the ADRe profiles. Pharmacy. 2018; 6(3):102 10.3390/pharmacy6030102
    1. Jordan S, Banner T, Gabe-Walters M, Mikhail JM, Panes G, Round J, et al. Medicines’ Management Group SU: Nurse-led medicines’ monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study. PloS ONE. 2019; 14(9):e0220885 10.1371/journal.pone.0220885
    1. Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, Picek A, et al. Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring. The Scientific World Journal. 2014; 843621 10.1155/2014/843621
    1. Jordan S, Gabe-Walters ME, Watkins A, Humphreys I, Newson L, Snelgrove S, et al. Nurse-Led medicines’ monitoring for patients with dementia in care homes: a pragmatic cohort stepped wedge cluster randomised trial. PLoS ONE. 2015; 10(10):e0140203 10.1371/journal.pone.0140203
    1. Gabe ME, Murphy F, Davies GA, Russell IT, Jordan S: Medication monitoring in a nurse-led respiratory outpatient clinic: pragmatic randomised trial of the West Wales Adverse Drug Reaction Profile. PloS ONE. 2014; 9(5):e96682 10.1371/journal.pone.0096682
    1. Cooper A, Edwards A, Williams H, Evans HP, Avery A, Hibbert P, et al. Sources of unsafe primary care for older adults: a mixed-methods analysis of patient safety incident reports. Age and ageing. 2017; 46(5):833–839. 10.1093/ageing/afx044
    1. Panesar SS, deSilva D, Carson-Stevens A, Cresswell KM, Salvilla SA, Slight SP, et al. How safe is primary care? A systematic review. BMJ Qual Saf. 2016; 25(7):544–53. 10.1136/bmjqs-2015-004178
    1. Thomas RE, Nguyen LT, Jackson D, Naugler C. Potentially Inappropriate Prescribing and Potential Prescribing Omissions in 82,935 Older Hospitalised Adults: Association with Hospital Readmission and Mortality Within Six Months. Geriatrics. 2020; 5(2):37 10.3390/geriatrics5020037
    1. National Institute for Health and Care Excellence (NICE). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guideline 5. London: NICE; 2015 . Cited 2 December 2020.
    1. Hakkarainen KM, Sundell KA, Petzold M, Hägg S. Prevalence and perceived preventability of self-reported adverse drug events—a population-based survey of 7099 adults. PLoS ONE. 2013; 8(9):e73166 10.1371/journal.pone.0073166
    1. Patel NS, Patel TK, Patel PB, Naik VN, Tripathi C. Hospitalizations due to preventable adverse reactions—a systematic review. European journal of clinical pharmacology. 2017; 73(4):385–398. 10.1007/s00228-016-2170-6
    1. Xu D, Kane R, Arling G. Relationship between nursing home quality indicators and potentially preventable hospitalisation. BMJ quality & safety. 2019; 28(7):524–533. 10.1136/bmjqs-2018-008924
    1. Beijer H, De Blaey C. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science. 2002; 24(2):46–54. 10.1023/a:1015570104121
    1. Gabe ME, Davies GA, Murphy F, Davies M, Johnstone L, Jordan S. Adverse drug reactions: treatment burdens and nurse‐led medication monitoring. Journal of Nursing Management. 2011; 19(3):377–392. 10.1111/j.1365-2834.2011.01204.x
    1. Brenner S, Detz A, López A, Horton C, Sarkar U. Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ quality & safety. 2012; 21(8):670–675. 10.1136/bmjqs-2011-000643
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. Journal of general internal medicine. 2005; 20(4):317–323. 10.1111/j.1525-1497.2005.30390.x
    1. Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. The American journal of medicine. 2005; 118(3):251–258. 10.1016/j.amjmed.2004.09.018
    1. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. Journal of the American Geriatrics Society. 2011; 59(8):1513–1520. 10.1111/j.1532-5415.2011.03500.x
    1. Aronson JK, Ferner RE. The law of mass action and the pharmacological concentration—effect curve: resolving the paradox of apparently non‐dose‐related adverse drug reactions. British journal of clinical pharmacology. 2016; 81(1):56–61. 10.1111/bcp.12706
    1. Gray SL, Hart LA, Perera S, Semla TP, Schmader KE, Hanlon JT. Meta‐analysis of interventions to reduce adverse drug reactions in older adults. Journal of the American Geriatrics Society. 2018; 66(2):282–288. 10.1111/jgs.15195
    1. Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. Age and ageing. 2018; 47(2):220–225. 10.1093/ageing/afx158
    1. Wu T-Y, Jen M-H, Bottle A, Molokhia M, Aylin P, Bell D, et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. Journal of the Royal Society of Medicine. 2010; 103(6):239–250. 10.1258/jrsm.2010.100113
    1. Office for National Statistics: Health State Life Expectancies by National Deprivation Deciles, England and Wales: 2015 to 2017. London: Office for National Statistics; 2018.
    1. Ryan AM, Krinsky S, Kontopantelis E, Doran T. Long-term evidence for the effect of pay-for-performance in primary care on mortality in the UK: a population study. The Lancet. 2016; 388(10041):268–274. 10.1016/S0140-6736(16)00276-2
    1. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database of Systematic Reviews. 2018;(9) Art. No.: CD008165 10.1002/14651858.CD008165.pub4
    1. Abbott RA, Moore DA, Rogers M, Bethel A, Stein K, Coon JT. Effectiveness of pharmacist home visits for individuals at risk of medication-related problems: a systematic review and meta-analysis of randomised controlled trials. BMC health services research. 2020; 20(1):39 10.1186/s12913-019-4728-3
    1. Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL. An evaluation of an adapted US model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study). Journal of the American Geriatrics Society. 2010; 58(1):44–53. 10.1111/j.1532-5415.2009.02617.x
    1. Monteiro L, Maricoto T, Solha I, Ribeiro-Vaz I, Martins C, Monteiro-Soares M. Reducing potentially inappropriate prescriptions for older patients using computerized decision support tools: systematic review. Journal of medical Internet research. 2019; 21(11):e15385 10.2196/15385
    1. Hanjani LS, Long D, Peel NM, Peeters G, Freeman CR, Hubbard RE. Interventions to optimise prescribing in older people with dementia: a systematic review. Drugs & Aging. 2019; 36(3):247–267.
    1. Rieckert A, Reeves D, Altiner A, Drewelow E, Esmail A, Flamm M, et al. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. bmj. 2020; 369:m1822 10.1136/bmj.m1822
    1. Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of Fall Risk—Increasing Drugs Around a Fall‐Related Injury in Older Adults: A Systematic Review. Journal of the American Geriatrics Society. 2020; 10.1111/jgs.16369
    1. Horton T, Illingworth J, Warburton W. The spread challenge. London: Health Foundation; 2018.
    1. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. Standards for Quality Improvement Reporting Excellence 2.0: revised publication guidelines from a detailed consensus process. Journal of surgical research. 2016; 200(2):676–682.
    1. Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. International nursing review. 2004; 51(4):208–221. 10.1111/j.1466-7657.2004.00251.x
    1. Jordan S, Vaismoradi M, Griffiths P. Adverse Drug Reactions, Nursing and Policy: A NarrativeReview. 2016. Annals of Nursing and Practice. 2016; 3(3):1050–55.
    1. Curtis L, Burns A: Unit Costs of Health and Social Care 2019. Personal Social Services Research Unit (PSSRU), Kent, UK: 2019 176 pp. ISBN 978-1-911353-10-2. 10.22024/UniKent/01.02.79286.
    1. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. The Annals of Family Medicine. 2004; 2(3):204–208. 10.1370/afm.141
    1. IBM: SPSS statistics for Windows. Armonk, New York: IBM, Corp; 2013.
    1. Altman DG: Practical statistics for medical research. London: Chapman and Hall, 1991.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative research in psychology. 2006; 3(2):77–101.
    1. Foss C, Ellefsen B. The value of combining qualitative and quantitative approaches in nursing research by means of method triangulation. Journal of advanced nursing. 2002; 40(2):242–248. 10.1046/j.1365-2648.2002.02366.x
    1. Denzin NK. Triangulation 2.0. Journal of mixed methods research. 2012; 6(2):80–88.
    1. Medical Research Council (MRC). MRC ethics guide: Medical research involving adults who cannot consent. London: MRC; 2007.
    1. Jones R, Moyle C, Jordan S. Nurse-led medicines monitoring: a study examining the effects of the West Wales Adverse Drug Reaction Profile. Nursing Standard. 2016; 31(14):42–53. 10.7748/ns.2016.e10447
    1. O’Dwyer M, McCallion P, McCarron M, Henman M. Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research. Therapeutic advances in drug safety, 2018; 9(9):535–557. 10.1177/2042098618782785
    1. Piggott KL, Mehta N, Wong CL, Rochon PA. Using a clinical process map to identify prescribing cascades in your patient. Bmj. 2020; 368:m261 10.1136/bmj.m261
    1. Lucas B, Nacer H. The habits of an improver: thinking about learning for improvement in healthcare. London: The Health Foundation; 2015.
    1. Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, et al. Feasibility of implementing the patient-reported outcomes version of the common terminology criteria for adverse events in a multicenter trial: NCCTG N1048. Journal of Clinical Oncology. 2018; 36(31):3120 10.1200/JCO.2018.78.8620
    1. Scottish Government 2018. Polypharmacy Guidance: Realistic Prescribing 3rd edition Scottish government, NHS; Scotland, Edinburgh: Cited 2nd December 2020.
    1. National Health Service (NHS) England and NHS Improvement: The NHS patient safety strategy. Safer culture, safer systems, safer patients Clinical Guideline 43/19. London: NICE; 2019.
    1. Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in older adults with cardiovascular disease. Journal of the American College of Cardiology. 2019; 73(20):2584–2595. 10.1016/j.jacc.2019.03.467
    1. Eiring Ø, Landmark BF, Aas E, Salkeld G, Nylenna M, Nytrøen K. What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. BMJ open. 2015; 5(4):e007848 10.1136/bmjopen-2015-007848
    1. Jordan S, Hughes D. Continuing professional education and the everyday realities of practice In: Allen D, Hughes D, Jordan S, Prowse M, Snelgrove S editors. Nursing and the Division of Labour in Healthcare. Basingstoke, UK: Palgrave; 2002: pp.129–150.
    1. Mitchell JC. Case and situation analysis. The sociological review. 1983; 31(2):187–211.
    1. Coles E, Anderson J, Maxwell M, Harris FM, Gray NM, Milner G, et al. The influence of contextual factors on healthcare quality improvement initiatives: a realist review. Systematic Reviews. 2020; 9:1–22.
    1. Royal Pharmaceurical Society (RPS). Improving patient outcomes—the better use of multi‐compartment compliance aids. London: Royal Pharmaceutical Society Great Britain, Cited 2 December 2020.
    1. General Medical Council (GMC). Good practice in prescribing and managing medicines and devices., London: General Medical Council; 2013. Cited 2 December 2020.
    1. Care Quality Commission. Medicines in health and adult social care. Care Quality Commission, Newcastle upon Tyne, United Kingdom; 2019. Medicines in health and social care | Care Quality Commission () Cited 2 December 2020.
    1. De Baetselier E, Van Rompaey B, Batalha LM, Bergqvist M, Czarkowska-Paczek B, De Santis A et al. EUPRON: nurses’ practice in interprofessional pharmaceutical care in Europe. A cross-sectional survey in 17 countries. BMJ Open. 2020;10(6):e036269 10.1136/bmjopen-2019-036269
    1. Logan V, Keeley S, Akerman K, De Baetselier E, Dilles T, Griffin N, et al. Did we do everything we could have? Nurses’ contributions to medicines optimization: A mixed‐methods study. Nurs Open. 2020; 00: 1–15. 10.1002/nop2.664
    1. Disalvo D, Luckett T, Bennett A, Davidson PM, Agar M. Multidisciplinary perspectives on medication-related decision-making for people with advanced dementia living in long-term care: a critical incident analysis. European journal of clinical pharmacology. 2020; 76(4):567‐578. 10.1007/s00228-019-02820-z
    1. Paque K, Vander Stichele R, Elseviers M, Pardon K, Dilles T, Deliens L, et al. Barriers and enablers to deprescribing in people with a life-limiting disease: a systematic review. Palliative medicine. 2019; 33(1):37–48. 10.1177/0269216318801124
    1. Hughes D, Jordan M, Logan PA, Willson A, Snelgrove S, Storey M, et al. Looking for the “Little Things”: A Multi-Disciplinary Approach to Medicines Monitoring for Older People Using the ADRe Resource. Geriatrics. 2020; 5(4):E79 10.3390/geriatrics5040079
    1. Braithwaite J, Glasziou P, Westbrook J. The three numbers you need to know about healthcare: the 60-30-10 Challenge. BMC medicine. 2020; 18(1):102 10.1186/s12916-020-01563-4
    1. Hart JT. A New Kind of Doctor In: Black N, Boswell D, Gray A, Murphy S, Popay J editors Health and disease: a reader. Milton Keynes, UK: Open University Press; 1981. pp.129–136.
    1. Lloyd T, Conti S, Santos F, Steventon A. Effect on secondary care of providing enhanced support to residential and nursing home residents: a subgroup analysis of a retrospective matched cohort study. BMJ quality & safety. 2019; 28(7):534–546. 10.1136/bmjqs-2018-009130
    1. Aspinall SL, Hanlon JT, Niznik JD, Springer SP, Thorpe CT. Deprescribing in older nursing home patients: Focus on innovative composite measures for dosage deintensification. Innovation in Aging. 2017; 1(2):igx031 10.1093/geroni/igx031
    1. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS medicine. 2016; 13(8):e1002101 10.1371/journal.pmed.1002101
    1. Jennings E, Gallagher P, O’Mahony D. Detection and prevention of adverse drug reactions in multi-morbid older patients. Age and ageing. 2019; 48(1):10–13. 10.1093/ageing/afy157
    1. Jordan S, Hughes D. Using bioscience knowledge in nursing: actions, interactions and reactions. Journal of Advanced Nursing. 1998; 27(5):1060–1068. 10.1046/j.1365-2648.1998.00611.x
    1. Jordan S, Hughes D. Community teamwork is key to monitoring the side-effects of medication. Nursing times. 2000; 96(15):39–40.
    1. Rossi PH. The iron law of evaluation and other metallic rules. Research in Social Problems and Public Policy. 1987; 4: 3–20.
    1. National Assembly for Wales (NAfW). Use of antipsychotic medication in care homes. NAfW, Cardiff; 2018. Cited 2 December 2020.
    1. Royal Pharmaceutical Society (RPS), The right medicine: Improving care in care homes. RPS, London; 2016. Cited 2 December 2020.
    1. Garrett D MN, Thompson R. Commitment to Care of People living with Dementia SPACE Principles Royal College of Nursing (RCN) Professional Resource: London: RCN; 2019.
    1. NHS England. Coronavirus: second phase of NHS response to COVID-19. 29 Apr 2020. . Cited 28.November 2020.
    1. Iacobucci G. Covid-19: GPs have a fortnight to start organising weekly care home reviews, says NHS. BMJ. 2020; 369:m1827 10.1136/bmj.m1827
    1. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions. Drug safety. 2008; 31(1):21–37. 10.2165/00002018-200831010-00003
    1. Cooper J, Williams H, Hibbert P, Edwards A, Butt A, Wood F, et al. Classification of Patient-Safety Incidents in Primary care/Classification Des Incidents Lies a la Securite Des Patients Dans le Cas Des Soins primaires/Clasificacion De Incidentes Que Afectan a la Seguridad del Paciente En la Atencion Primaria. Bulletin of the World Health Organization. 2018; 96(7):498.
    1. Ellwood A, Airlie J, Cicero R, Cundill B, Ellard DR, Farrin A, et al. Recruiting care homes to a randomised controlled trial. Trials. 2018; 19(1):1–10.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다